– USA, UT – Central Logic, the healthcare industry’s leading provider of innovative transfer center and on-call scheduling technology solutions, has named University of Utah professor and James Lee Sorenson’s Presidential Chair Paul Brown to its Board of Directors.
Brown teaches entrepreneurship and strategy at the University of Utah’s David Eccles School of Business and is a Venture Partner with Apple Tree Partners, a New York-based venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services.
Prior to joining the University of Utah, Paul served as founder and CEO of Sandbox Innovation Partners, an innovation consulting practice that matches Fortune 500 clients with competitively relevant startups. He also founded and co-managed Blue Cross Blue Shield Ventures, a $300M healthcare venture capital fund.
“Central Logic is rapidly growing with the recent launch of Patient Connect and Data Intelligence – first-of-their-kind technologies that operationalize care coordination. Paul’s addition to the Central Logic Board comes at the perfect time. He has built his career on successes in the healthcare industry, believes in our strategy for the future and is excited about the direction I am taking the company. His industry knowledge and deep provider relationships will only help us grow our market presence as an industry leader and strategic partner for all healthcare systems,“ said Jennifer Holmes, Central Logic, Chairman and CEO. “I am really looking forward to working closely with Paul and our Board as we continue to expand our technology solutions.”
“We welcome Paul’s expertise and experience. His vision aligns with where Central Logic is headed as a company and we believe he will be an important voice in helping us meet and exceed our client’s expectations,” Holmes added.
Brown has worked with nearly 40 healthcare startup companies and has 25 years of experience as a healthcare executive, venture capitalist, entrepreneur, lawyer and professor. He was a partner in the Chicago office of Kirkland & Ellis LLP for nine years and then went on to serve ten years as a vice president at the national Blue Cross and Blue Shield organization.
“I’m excited to join Central Logic’s Board of Directors,” said Brown. “I believe their products are bridging a critical gap in care analytics and documentation that no one else is effectively addressing in the market today.”
Central Logic’s board is the most recent in a long line of board positions for Brown. He is a director for CleanSlate Centers, TripleCare and AMP Media Services, advises Cure Forward, Well, Braeburn Pharmaceuticals, and Advantia Health, and is a mentor for Village Capital and Healthbox.
Previously, Brown was a director for Capson, Phreesia, PatientCo, Nexidia (acquired by NICE Systems), Bloom Health (acquired by three Blue health plans), and a board observer for Initiate Systems (acquired by IBM).
Paul earned dual bachelor’s degrees from The University of Utah and a law degree from the Northwestern University Pritzker School of Law.
About Central Logic
As the industry’s leading provider of innovative transfer center and on-call scheduling technology, Central Logic’s team works collaboratively with more than 500 hospitals and thousands of healthcare customers or relationships – including physicians, administrators, and healthcare staff – to design and implement patient flow software solutions that increase admissions and capacity. Founded in 2005, the company helps hospitals and systems measurably increase the number of patient admissions and patient transfer volumes while maximizing hospital staffing, efficiency and care coordination.
For more information, visit www.centrallogic.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.